MyShare
Key factors
| sym | HJLI |
| exch | US |
| MCap | 98.25M |
| Beta | 1.540 |
| EPS | -2.70 |
| Div date | 0000-00-00 |
Yesterday
| sym | HJLI |
| exch | US |
| 50 Day MA | 9.021 |
| 200 Day MA | 6.951 |
| 52 Week High | 17.68 |
| 52 Week Low | 4.99 |
| Target Price | 26.0 |
| Market Cap Mln | 98.25 |
Share statistics
| Shares Outstanding | 9466.24K |
| Shares Float | 5736.85K |
| Percent Institutions | 23.16 |
| PercentInsiders | 9.636 |
| SharesShort | 710.90K |
| Short Ratio | 2.54 |
| Shares Short Prior Month | 479.51K |
| Short Percent | 8.370 |
Income
| Quarterly Revenue Growth YOY | -100.0 |
| Gross Profit TTM | -4252.2K |
| EBITDA | -6392.2K |
| Diluted Eps TTM | -2.70 |
earning
| EPS Estimate Current Quarter | -0.34 |
| EPS Estimate Current Year | -1.37 |
| EPS Estimate Next Quarter | -0.33 |
| EPS Estimate Next Year | -1.04 |
| Earnings Share | -2.70 |
Dividend
| Dividend Date | 2020-11-30 |
| Last Split Date | 2020-11-30 |
| Last Split Factor | 1:25 |
business
| Enterprise Value Revenue | 159.37 |
| Book Value /share | 4.801 |
| Price Book MRQ | 2.274 |
| Price Sales TTM | 216.91 |
| ReturnOnAssetsTTM | -0.30 |
| ReturnOnEquityTTM | -0.55 |
Sector
| Gic Group | Health Care Equipment & Services |
| Gic Industry | Health Care Equipment & Supplies |
| Gic Sector | Health Care |
| Gic Sub Industry | Health Care Equipment |
| Industry | Medical Devices |
| Sector | Healthcare |
Codes
| ISIN | US29415J1060 |
| CIK | 1661053 |
| Code | HJLI |
| CUSIP | 41015N106 |
| Employer Id Number | 33-0936180 |
| CountryISO | US |
| Currency Code | USD |
| Currency Name | US Dollar |
| Exchange | NASDAQ |
| Currency Symbol | $ |
fund
| Type | Common Stock |
| UpdatedAt | 2021-12-03 |
| Home Category | Domestic Primary |
info
| Fiscal Year End | December |
| Full Time Employees | 19.0 |
| IPODate | 2018-05-31 |
| International Domestic | Domestic |
| MostRecent Quarter | 2021-09-30 |
Contact
| Name | Hancock Jaffe Laboratories Inc |
| Address | 70 Doppler, Irvine, CA, United States, 92618 |
| Country Name | USA |
| Phone | 949 261 2900 |
| Web URL | www.hancockjaffe.com |
| Logo URL | /img/logos/US/HJLI.png |
Hancock Jaffe Laboratories, Inc., a medical device company, develops and sells tissue-based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It engages in the development and manufacture of bioprosthetic medical devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries. The company was founded in 1987 and is headquartered in Irvine, California. Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.